Indeed, Batf3−/− mice showed impaired rejection of FGL2KO tumors because of significantly reduced CD103+/CD8+ DCs in the brain and TDLNs, showing impairment in initiating the CD8+ T cell response against tumor cells in the absence of Batf3. This evidence concerns the gene BATF3 and neoplasm.